⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

December 4, 2018Expert Review of Molecular DiagnosticsOpen Access

Assay challenges (and opportunities) with non-factor VIII therapies for Hemophilia A

Maria M. Aleman Nina C. Leksa Robert Peters Joe Salas

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Replacement factor VIII (FVIII) – plasma-derived or recombinant, with or without half-life extension – is the standard treatment for hemophilia A patients. Because FVIII level is strongly correlate...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aleman et al. (2018) studied this question.

synapsesocial.com/papers/6a9483c318fa85d8c46e5b48 https://doi.org/10.1080/14737159.2019.1554436

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysisReview · 2015 · 234 citations
2Evaluation of Thrombin Generation Assay in Patients With HemophiliaCross-Sectional Study · 2014 · 18 citations
3Monitoring rFVIII prophylaxis dosing using global haemostasis assaysOriginal Research · 2013 · 34 citations
4Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotypeLate-Phase Clinical Trial · 2017 · 6 citations
5Clot waveform analysis: Where do we stand in 2017?Review · 2017 · 64 citations
6Parallel use of by‐passing agents in haemophilia with inhibitors: a critical reviewReview · 2011 · 70 citations
7Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigensOriginal Research · 2017 · 213 citations
8Emicizumab Prophylaxis in Hemophilia A with InhibitorsHuman Clinical Trial · 2017 · 1,132 citations
9MicroRNA-based point-of-care diagnostics for emerging and re-emerging infectious diseases: from biomarker discovery to clinical implementationExpert Review of Molecular Diagnostics · 2026
10Biomarker-led advances in renal cell carcinoma diagnosis, progression monitoring and therapeutic decision-makingExpert Review of Molecular Diagnostics · 2026

More from Expert Review of Molecular Diagnostics

More from Sanofi (United States)